🎧 Prêmio ouvinte do ano TdC

🧡 Queremos celebrar o tempo que passamos juntos em 2025.

🎁 Mostre que você é ouvinte raiz para concorrer a um kit exclusivo (camisa, caneca, caderno e caneta) na sua casa.

Como participar:
1. Poste sua Retrospectiva do TdC nos Stories.
2. Marque o @tadeclinicagem (seu perfil precisa estar público).
Você já estará concorrendo ao sorteio do kit completo.

Serão 2 vencedores:
🏆 Prêmio ouvinte raiz: 1 Kit para o ouvinte que mais escutou o TdC em 2025
🎲 1 Kit será sorteado entre todos que participarem do desafio

Informações adicionais:
A data limite para compartilhar será dia 15 de dezembro.
Já vai se preparando pra promoção de 2026! 

Marcela Belleza e Matheus Rezende convidam Daniela Harsanyi, residente de Cardiologia pelo Incor, para falar sobre atualizações no tratamento ambulatorial de insuficiência cardíaca.

Referências:
1. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC, European Heart Journal, Volume 44, Issue 37, 1 October 2023, Pages 3627–3639. https://doi.org/10.1093/eurheartj/ehad195
2. Anker SD, et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med. 2021;385(16):1451-1461. doi:10.1056/NEJMoa2107038
3. Anker SD, et al. Systematic review and meta-analysis of intravenous iron therapy for patients with heart failure and iron deficiency. Nat Med. 2025 Aug;31(8):2640-2646. doi:10.1038/s41591-025-03671-1
4. Armstrong PW, et al. Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2020;382(20):1883-1893. doi:10.1056/NEJMoa1915928
5. Bavendiek U, et al. Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2025;393(12):1155-1165. doi:10.1056/NEJMoa2415471
6. Belfort D, et al. Carvedilol as Single Therapy for Heart Failure With Improved Ejection Fraction: A Randomized Clinical Trial (CATHEDRAL-HF). J Am Coll Cardiol HF. Published online May 14, 2025. doi:10.1016/j.jchf.2025.02.022
7. Butler J, et al. Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial. Eur Heart J. 2022;43(41):4362-4373. doi:10.1093/eurheartj/ehac401
8. Comitê Coordenador da Diretriz de Insuficiência Cardíaca, Rohde LEP, Montera MW, et al. Diretriz Brasileira de Insuficiência Cardíaca Crônica e Aguda. Arq Bras Cardiol. 2018;111(3):436-539. doi:10.5935/abc.20180190
9. Ferreira J, et al. Sodium-Glucose Cotransporter 2 Inhibitor With and Without an Aldosterone Antagonist for Heart Failure With Preserved Ejection Fraction: The SOGALDI-PEF Trial. JACC. 2025 Aug;86(5):320–333.
10. Halliday BP, et al. Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial. Lancet. 2019;393(10166):61–73.
11. Heidenreich PA, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. Circulation. 2022;145(18):e895-e1032. doi:10.1161/CIR.0000000000001063
12. Kalra PR, et al. Lancet. 2022;400(10369):2199–2209. Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial. 
13. Kosiborod MN, et al. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2023;389(12):1069-1084. doi:10.1056/NEJMoa2306963
14. Kosiborod MN, et al. Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials. Lancet. 2024;404(10456):949-961. doi:10.1016/S0140-6736(24)01643-X
15. Maddox TM, et al. 2024 ACC Expert Consensus Decision Pathway for Treatment of Heart Failure With Reduced Ejection Fraction. J Am Coll Cardiol. 2024;83(15):1444-1488. doi:10.1016/j.jacc.2023.12.024
16. Marcondes-Braga FG, et al. Atualização de Tópicos Emergentes da Diretriz Brasileira de Insuficiência Cardíaca – 2021. Arq Bras Cardiol. 2021;116(6):1174-1212.
17. Marcondes-Braga FG. Sequenciamento do Tratamento Farmacológico da Insuficiência Cardíaca com Fração de Ejeção Reduzida. ABC Heart Fail Cardiomyop. 2022;2(1):31-35.
18. McMurray JJV, Packer M. How Should We Sequence the Treatments for Heart Failure and a Reduced Ejection Fraction?: A Redefinition of Evidence-Based Medicine. Circulation. 2021;143(9):875-877. doi:10.1161/CIRCULATIONAHA.120.052926
19. Mebazaa A, et al. Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised trial. Lancet. 2022;400(10367):1938-1952. doi:10.1016/S0140-6736(22)02076-1
20. Packer M, et al. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2025;392(5):427-437. doi:10.1056/NEJMoa2410027
21. Ponikowski P, et al. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. Lancet. 2020;396(10266):1895-1904. doi:10.1016/S0140-6736(20)32339-4
22. Solomon SD, et al. Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial. Eur J Heart Fail. 2021;23(7):1217-1225. doi:10.1002/ejhf.2249
23. Solomon SD, et al. Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med. 2024;391(16):1475-1485. doi:10.1056/NEJMoa2407107
24. Writing Committee, et al. 2024 ACC Expert Consensus Decision Pathway on Clinical Assessment, Management, and Trajectory of Patients Hospitalized With Heart Failure Focused Update. J Am Coll Cardiol. 2024;84(13):1241-1267. doi:10.1016/j.jacc.2024.06.002
25. Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003;362(9386):777-781. doi:10.1016/S0140-6736(03)14285-7